Cipla Ltd (NSE: CIPLA) faced a significant pullback on April 4, 2025, falling back below the ₹1,437 support zone as broader market sentiment turned risk-averse. The pharma giant, which had recently attempted to reclaim higher resistance zones near ₹1,490, failed to sustain upside momentum, triggering a reversal that has now pushed the stock toward key demand levels.
Sectorwide Pharma Surge Sparked by Trump’s Announcement
Earlier this week, Indian pharmaceutical stocks witnessed a broad-based rally following a policy announcement by former U.S. President Donald Trump, who hinted at increased support for affordable generic drug imports. The news boosted sentiment across India’s pharma space, with frontline stocks like Cipla, Sun Pharma, and Dr. Reddy’s Laboratories seeing strong buying interest.
However, Cipla’s current pullback suggests that profit booking has set in, particularly as the broader market digests the announcement’s macro implications.
Cipla Technical Analysis
Resistance Levels:
- ₹1,437.90 – Short-term ceiling, rejected today
- ₹1,491.70 – Mid-term resistance, recent failed breakout
- ₹1,534.75 – Key rejection zone from February
Support Zones:
- ₹1,390.95 – Immediate short-term support
- ₹1,366.50 – Critical support zone, held since December
- ₹1,300.00 (psychological) – Clean round-number floor, long-term buyers’ zone
Outlook: Watch ₹1,390 as Crucial Pivot Zone
With RSI nearing oversold and price approaching a strong support confluence, the coming sessions could define the next directional bias. Traders should monitor for either:
- Bullish divergence near support, suggesting potential reversal, or
- A breakdown below ₹1,366, confirming deeper downside extension.
Until a decisive move emerges, Cipla remains in a range-bound structure, oscillating between ₹1,366 and ₹1,490—a pattern traders can exploit with tight stop-losses and disciplined entries.
The post Cipla Share Price Faces Technical Rejection After Short-Term Rally appeared first in UK on InvestingCube.